http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005016951-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d05953717f1c41d297e1cc9ff8925996
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0751e746fc1203900f1967e3021acf63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2739952d7f6ecfc0df634ce212e0e3f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e8941527773eaaf15d85a59df11e43
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-26
filingDate 2004-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a3966e7b8ade6bf7900ecfef4efdb91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d925b32bf8463df4a1290c7f9db6bf36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3246603f72640c17c329110e36e16fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57d802f9c7b191dc8b2faeba5ba3f70c
publicationDate 2005-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2005016951-A3
titleOfInvention Anti-ghrelin fab antibodies
abstract Monoclonal antibodies, including humanized antibodies, which preferentially bind acetylated human ghrelin with respect to unacylated human ghrelin are disclosed. These antibodies have high affinity for acylated human ghrelin, a slow off rate for acylated human ghrelin dissociation and neutralize an acylated human ghrelin activity. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antigen-binding portions, of the invention are useful for neutralizing ghrelin activity, e.g., in a human subject suffering from a disorder in which ghrelin activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant anti-ghrelin antibodies are also encompassed by the invention.
priorityDate 2003-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1197496-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100136596
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID798613
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426285296
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID58991
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID281192
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71728433

Total number of triples: 33.